EUCTR2008-001032-12-DE进行中（未招募）1 期
Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer - PANTHERA
niversitätsklinikum Schleswig-Holstein0 个研究点目标入组 47 人开始时间: 2008年7月29日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 47
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Diagnosis of metastatic, histologically proven follicular/papillary or anaplastic thyroid cancer without clinically meaningful surgical or radiotherapeutic options and/or no amenability for radio-iodine therapy.
- •2.No other forms of chemotherapy or investigational anticancer agents therapy for at least 4 weeks before enrollment in study.
- •3.Performance status of 0 to 2 on the ECOG scale (Protocol Appendix B).
- •4.Evidence of measurable disease according to the RECIST criteria, which means:
- •Patients must have clinically and/or radiographically documented measurable disease. At least one site of disease must be unidimensionally measurable as follows:
- •X-ray, physical exam> 20 mm
- •Spiral CT scan> 10 mm
- •Non-spiral CT scan> 20 mm
- •All radiology studies must be performed within 28 days prior to registration (35 days if negative).
- •5.Prior radiation therapy and surgery allowed if completed at least 2 weeks prior to study enrollment, prior radioiodine treatment at least 3 months prior to study enrollment and patients must have recovered from the acute toxic effects of the treatment prior to study entry.
- •6.Adequate organ function including the following:
- •Adequate bone marrow reserve: platelets 100 x 109/L, hemoglobin 9 g/dl, absolute granulocyte count (AGC) >1.5 x 109/L.
- •Hepatic: bilirubin ?1.5 times upper limit of normal, aspartate transaminase (AST) and alanine transaminase (ALT) ?3.0 times normal (AST and ALT ?5.0 times normal is acceptable if due to liver metastases).
- •Renal: calculated creatinine clearance ?45 ml/min, using MDRD-formula (see http://nephron.com/cgi-bin/MDRDSIdefault.cgi)
- •7.No active infection (at the discretion of the investigator) or current central nervous system (CNS) metastases or history of central nervous system metastases or other serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
- •8.No breast feeding nor pregnancy. For women of childbearing potential a negative serum pregnancy-test has to be performed 7 days prior to inclusion into the study.
- •9.No coexisting second malignancy or history of prior malignancy within the last 5 years. (Excluding basal or squamous cell carcinoma of the skin, superficial bladder cancer and in situ carcinoma of the cervix with no evidence of recurrence).
- •10.For men and women of childbearing potential appropriate contraceptive precautions should be taken during the trial and for 3 months afterwards.
- •11.No significant cardiovascular disease in the form of abnormal electrocardiogram (ECG) coupled with clinical features of recent or recurrent symptomatic cardiac disease (including myocardial infarction within the last year, uncontrolled angina, arrhythmia or hypertension, severe congestive heart failure (NYHA >3)).
- •12.No evidence of peripheral neuropathy greater than CTC Grade 1.
- •13.No prior taxane and/or pemetrexed (Alimta?) therapy.
- •14.Ability to discontinue administration of acetysalicylate (Aspirin®) and other nonsteroidal anti-inflammatory agents (NSAID) in case of higher daily dosages (e.g. > 1.3 g), the day of, for 2 days before, and 2 days after the dose of pemetrexed (Alimta?) (5 days prior for long-acting agents such as piroxicam).Exceptions for selective cyclooxygenase II-inhibitors in analgesic treatment may be discussed.
- •15.No clinically significant effusions (pleural or peritoneal), or albumin <2.5 g/dl at the time of study treatment application. The drainage of effusions
排除标准
- 未提供
研究者
相似试验
已完成
不适用
A randomized phase II trial of Pemetrexed or Pemetrexed plus Carboplatin followed by maintenance Pemetrexed therapy for elderly chemotherapy naive stage IIIB/IV or postoperative recurrence non-squamous non-small cell lung cancer patientsJPRN-UMIN000008928Yushima Lung Cancer Oncology Group(YLOG)100
进行中（未招募）
不适用
A randomized phase II trial of pemetrexed with or without PF-3512676 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of one prior chemotherapy regimen for advanced diseaseTreatment of patients with locally advanced or metastatic non-small lung cancer (NSLC) after failure of one prior chemotherapy regimen for advanced diseaseMedDRA version: MedLevel: VTcClassification code 10061873EUCTR2006-001588-52-DEPfizer Pharma GmbH130
进行中（未招募）
不适用
A Randomized Phase 2 Study of Pemetrexed in Combination with Cisplatin or Carboplatin in the First Line Therapy of Advanced NSCLCadvanced NSCLC of Stage IIIb or IV undergoing first line chemotherapyEUCTR2006-002818-35-DEilly Deutschland GmbH
进行中（未招募）
不适用
A Randomized Phase 2 Study of Pemetrexed in Combination with Cisplatin or Carboplatin as Adjuvant Chemotherapy in Patients with Completely Resected Stage Ib or II Non-Small Cell Lung Cancer - Not availableEUCTR2005-002911-26-DEEli Lilly and Company Limited112
进行中（未招募）
不适用
A Phase 1 and 2 Clinical Trial of ALIMTA (Pemetrexed) in Combination with Carboplatin in Patients with Recurrent Ovarian or Primary Peritoneal Cancer(Sweden will participate in Phase 2 of this trial, only)platinum sensitive recurrent ovarian or primary peritoneal cancerMedDRA version: 8.1Level: LLTClassification code 10033130Term: Ovarian cancer NOSEUCTR2004-002782-20-SEEli Lilly and Company Limited85